DermTech's Utility Study Published in JAMA Dermatology

LA JOLLA, Calif., April 27, 2017 /PRNewswire/ -- DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the publication of  "Utility and Decision Impact of a Non-Invasive 2-Gene Molecular Assay for Cutaneous Melanoma," in the Journal of the American Medical Association Dermatology (Ferris et al. JAMA Dermatology DOI170012). Dermatologists who incorporated the pigmented lesion assay into their biopsy decision improved biopsy specificity from 32.1% to 56.9% (p<0.001), and also improved biopsy sensitivity by 4% (p=0.01).

"The utility study demonstrates that even pigmented lesion experts surgically biopsy about half as often and miss fewer melanomas when adding the pigmented lesion assay to their decision process," said Laura Korb Ferris, MD, PhD, the study's lead author and Associate Professor of Dermatology at the University of Pittsburgh. "We are excited to offer this non-invasive tool to aid dermatologists in the difficult diagnosis of melanoma."

About DermTech

DermTech is the global leader in molecular dermatology. We market and develop non-invasive gene expression tests to aid the clinical diagnosis of skin cancer, assess inflammatory diseases, and to personalize drug treatment. DermTech's technology allows the analysis of skin biopsy samples collected non- invasively using an adhesive patch. Our mission is to transform dermatology by delivering highly accurate, objective information to physicians to improve care and reduce costs.  For additional information visit: www.dermtech.com.  

Contacts:

DermTech, Inc.
Sarah Dion, MBA
VP, Sales and Marketing
(858) 450-4222
[email protected]

SOURCE DermTech, Inc.

Related Links

http://www.dermtech.com